Pelizaeus-Merzbacher Disease (PMD)
A rare, progressive, degenerative central nervous system disorder in which coordination,
motor abilities, and intellectual function deteriorate. The disease is caused by
a mutation in the gene that controls the production of a myelin protein called proteolipid
protein-1 (PLP1). PMD is inherited as an X-linked recessive trait; the affected individuals
are male and the mothers are carriers of the PLP1 mutation.
Severity and onset of the disease ranges widely, depending on the type of PLP1 mutation.
PMD is one of a spectrum of diseases associated with PLP1, which also includes Spastic
Paraplegia Type 2 (SPG2). The PLP1-related disorders span a continuum of neurologic
symptoms that range from severe central nervous system involvement (PMD) to progressive
weakness and stiffness of the legs (SPG2). [1]
There are four general classifications within this spectrum of diseases. In order
of severity, they are:
- Connatal PMD, which is the most severe type and involves delayed mental and physical
development and severe neurological symptoms.
- Classic PMD, in which the early symptoms include muscle weakness, involuntary movements
of the eyes (nystagmus), and delays in motor development within the first year of
life.
- Complicated SPG2, which features motor development issues and brain involvement.
- Pure SPG2, which includes cases of PMD that do not have neurologic complications.
[1]
Noticeable changes in the extent of myelination can be detected by MRI analyses of
the brain. Additional symptoms of PMD may include slow growth, tremor, failure to
develop normal control of head movement, and deteriorating speech and mental function.
[1]
Treatment
There is no cure for Pelizaeus-Merzbacher disease, nor is there a standard course
of treatment. Treatment is symptomatic and supportive and may include medication
for movement disorders. [1]
Prognosis
The prognosis for those with the severe forms of Pelizaeus-Merzbacher disease is
poor, with progressive deterioration until death. On the other end of the disease
spectrum, individuals with the mild form, in which spastic paraplegia is the chief
symptom, may have nearly normal activity and life span. [1]
1. Ninds.nih
Top of Page